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Abstract Ever since Virchow introduced the entity myxo-
ma, abundant myxoid extracellular matrix (ECM) has been
recognized in various reactive and neoplastic lesions.
Nowadays, the term “myxoid” is commonly used in daily
pathological practice. But what do today’s pathologists
mean by it, and what does the myxoid ECM tell the
pathologist? What is known about the exact composition
and function of the myxoid ECM 150 years after Virchow?
Here, we give an overview of the composition and
constituents of the myxoid ECM as known so far and
demonstrate the heterogeneity of the myxoid ECM among
different tumors. We discuss the possible role of the
predominant constituents of the myxoid ECM and attempt
to relate them to differences in clinical behavior. Finally, we
will speculate on the potential relevance of this knowledge
in daily pathological practice.
Keywords Extracellularmatrix.Glycosaminoglycans.
Proteoglycan.Collagen.Myxofibrosarcoma.
Intramuscularmyxoma
Historical perspective
In his 1858 masterpiece Cellularpathologie, Rudolph
Virchow introduced the term “myxoma” to describe a soft
tissue tumor, histologically resembling the structure of the
umbilical cord (Figs. 1 and 2)[ 1]. This description of
myxoma was adopted in the seventh edition of the Medical
Lexicon by Robley Dunglison who remarkably added that
“[myxoma] was for the first time described in 1838 by
Johannes Müller as Collonema” [2]. Müller used the term
collonema (κολλα =g l u e )f o r“peculiar gelatinous
tumours, consisting of a remarkably soft gelatiniform
tissue, which trembles on being touched” [3]. Though this
description is applicable to most myxoid tumors, it holds
also for many nonmyxoid tumors and it is not particularly
clear which tumor type Müller had in mind. Today, it has
been generally accepted that it was indeed Virchow who
introduced myxoma as an entity. The introduction of this
new histological concept of tumors containing myxoid
(μύξα = “mucus” and ειδος = “resemblance”) areas soon
led to the recognition of new entities, such as myxadenoma,
myxochondroma, myxofibroma, and myxoneuroma [2].
The term myxosarcoma, introduced in 1802 by Bryant
[4], became reserved for malignant tumors and defined as
“a mucous transformation of round-celled sarcoma, malig-
nant, and of large volume, usually attacking the omentum
and the skin” [2]. Nowadays, myxoid changes/areas are
recognized in both benign and malignant neoplasms
(primarily classified as mesenchymal or epithelial) as well
as non-neoplastic (reactive) lesions (Fig. 3).
In his first description, Virchow had already recognized
the recurrent nature of some myxomatous tumors [1] and it
became clear that it was difficult to predict the exact clinical
behavior of these different tumors based on their myxoid
morphology alone. Subsequently, the terms myxoma and
myxosarcoma were used interchangeably till Arthur Stout
recognized this as unwise [5] because “myxomas do not
metastasize and there is no way to anticipate differences in
their growth energy from their histopathology.” Later
studies confirmed the distinction between both entities on
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DOI 10.1007/s00428-009-0822-ythe basis of macroscopical and microscopical features
(necrosis, nuclear atypia, and mitotic figures; Fig. 2)[ 6].
Today, myxoid tumors of soft tissue are classified according
to the World Health Organization (WHO) formulation
based on clinicopathological criteria and specific molecu-
lar/cytogenetic aberrations (Table 1)[ 7, 8]. So what is left
of the term “myxoid” 150 years after Virchow? What do
today’s pathologists mean by it, and what does the myxoid
extracellular matrix (ECM) tell the pathologist? What is the
exact composition of this myxoid ECM and does it have a
function? Here, we give an overview of the composition
and constituents of the myxoid ECM as known so far and
demonstrate the heterogeneity of the myxoid ECM among
different tumors. We discuss the possible role of the
predominant constituents of the myxoid ECM and attempt
to relate them to differences in clinical behavior. Finally, we
will speculate on the potential relevance of this knowledge
in daily pathological practice.
Composition of the myxoid extracellular matrix
Glycosaminoglycans and proteoglycans
Substantial progress in the study of the myxoid ECM was
made after the introduction of alcian blue staining in 1950
[9]. John Scott was one of the pioneers who used this
histochemical stain to distinguish between the different
glycosaminoglycans (GAGs) in tissue sections [10].
Kindblom et al. showed that the myxoid ECM of various
(non)neoplastic tissues, i.e., Wharton’s jelly and myxoid
tumors of soft tissue, contained large amounts of GAGs
Fig. 1 Timetable with key events in studies on myxoid tumors of soft
tissue. Though Müller already mentioned tumors with a macroscopi-
cally gelatinous appearance in 1838 [3], it was in 1858 when Virchow
introduced the term myxoma to describe tumors which morphologi-
cally resembled the jelly structure of the umbilical cord [1]. Ever
since, the term myxosarcoma, introduced by Bryant in 1802 was
reserved for the malignant counterparts [4]. Because of their
morphologically overlapping features, both terms were used inter-
changeably, which was mentioned by Stout in 1948 as unwise,
warranting for macroscopical and microscopical criteria for the
reliable differential diagnosis between the two entities [5]. The
relationship between myxomas and fibrous dysplasia was first
described in 1926 by Henschen [90], though it was Mazabraud who
proposed it as a syndrome in 1967 [91]. The association of cardiac/
cutaneous myxomas, hyperpigmentation of the skin, and endocrine
overactivity was only recognized in 1985 by Carney [43]. Progress in
the study of the myxoid ECM was made by the invention of the alcian
blue staining in 1950 by Steedman [9], and Scott who developed the
CEC method to distinguish the different GAGs in 1965 [10]. Based
upon this technique, Kindblom showed in 1975 that different bone and
soft tissue tumors (including myxoid ones) contained different GAGs
[11]. From the late 1980s, it became clear that the ECM is a key player
in tumor development and tumor progression, sustained by an
exponentially growing number of publications [40]. As myxoid areas
were now being recognized as an intrinsic part of a subset of tumors,
Weiss and Angervall simultaneously described the myxoid variant of
malignant fibrous histiocytoma/myxofibrosarcoma as a distinct entity
[92, 93]. Parallel to morphological classification, an increasing
number of myxoid tumors showed specific molecular genetics
aberrations, such as (activating) mutations and translocations. The
concept of malignant progression in myxoid tumors of soft tissue (i.e.,
myxoid liposarcoma) due to chromosomal instability and subsequent
secondary genetic events was described in 1990 by Orndal et al. [94].
Nowadays, classification of myxoid tumors of soft tissues is based
upon clinicopathological and molecular/cytogenetic aberrations as
published in the 2002 WHO classification [7]
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abundantly present in pericellular and extracellular matrices
and consist of unbranched polysaccharide chains of
disaccharides which are often sulfated. There are six
different types of GAGs: hyaluronic acid (HA), keratin
sulfate, chondroitin sulfate, dermatan sulfate, heparan
sulfate, and heparin [12]. GAGs form proteoglycans (PGs)
once covalently attached to specific core proteins. Core
proteins of PGs are synthesized in the endoplasmic reticulum
and post-translationally modified as they pass through the
Golgiapparatuswherehexuronicacidandhexosaminegroups
are attached. The exception is HA, which is synthesized
directly under the cytoplasmic membrane by the hyaluronic
acid synthetases 1, 2, and 3 [12]. The most common
classification of the different PGs is based upon the
properties of the core protein. The three main PG families
present in the ECM are lecticans, small leucine-rich
proteoglycans (SLRPs), and other ECM PG [13]. Lecticans
always contain both a hyaluronan-binding domain and a C-
type lectin domain. The lectican family includes: aggrecan,
versican, neurocan, and brevican that can be found at
different locations (Table 3)[ 12]. SLRPs can be found
extracellularly and intracellularly and at the cell surface.
They contain nine to 12 tandem repeats of leucine-rich
motifs which involve their collagen-binding domains. The
SLRP family includes decorin, biglycan, asporin, ECM
Fig. 2 Characteristic macroscopy and histomorphology of the myxoid
ECM. Rudolph Virchow introduced the term myxoma for those
tumors morphologically resembling Wharton's jelly of the umbilical
cord (a), which contains large amounts of GAGs as detected by alcian
blue (b). High-power image of Wharton's jelly showing abundant
myxoid ECM containing fibrillary collagens, interspersed between
myofibroblast-like stroma cells (c). Intramuscular myxoma character-
istically has a gelatinous appearance on cut surface (d) and is well
circumscribed towards its peripheral tissue (e). On higher magnifica-
tion, it shows the same abundant myxoid ECM as the umbilical cord
(c) and no significant atypia of the sparse tumor cells (f). Histological
criteria are still a hallmark of diagnosis, showing characteristic
lobulated, hypocellular morphology of grade I myxofibrosarcoma at
low magnification (g).Curvilinear blood vessels are often seen in
grade I myxofibrosarcoma (but are not diagnostic), whereas tumor
cells show vesicular, slightly atypical nuclei compared to intramuscu-
lar myxoma (h). Another hallmark of myxofibrosarcoma is areas with
abrupt transition of grade (i) which was already mentioned by Mentzel
et al. [95]
Virchows Arch (2010) 456:181–192 183protein 2, keratocan, proline/arginine-rich and leucine-rich
repeat proteins, osteoadherin, lumican, fibromodulin, opticin,
epiphycan, osteoglycin, podocan, chondroadherin, and nyc-
talopin [14]. ECM PGs do not show significant homology in
the content of their core proteins. Perlecan, agrin, and
collagen types XV and XVIII belong in this family [14].
Various GAGs and PGs have been identified in the myxoid
ECM (Table 2): HA is the most common; none of them are
specific for one particular lesion.
Collagens
One of the first papers addressing myxoma and its
malignant counterpart (“myxosarcoma”) mentioned the
presence of fibrillary collagens as a hallmark for differential
diagnosis [6]. Though this criterion did not last long,
collagens (κολλα = glue; γηνε = that which produces) are
a main component of the myxoid ECM. They are
characterized by their regular, triple-stranded helix of so-
called alpha-chains forming cord-like strands of 300 nm in
length and 1.5 nm in diameter. A separate group of
collagens is formed by the fibril-associated collagens with
interrupted triple helices (FACIT) and includes collagen
types XII and XIV. These collagens have several triple
helical domains (collagen type domains [Col]) separated by
nontriple helical domains (NC). All collagens contain large
amounts of proline and glycine as well as hydroxyproline
and hydroxylysine which are formed by post-translational
modification. Based on their biochemical differences, more
than 30 different types of collagens are recognized [15].
The most common types are I, II, III, and IV, which account
for 90% of all collagens in humans. Except for collagen II,
which is predominantly present in cartilage, collagen types
I, III, and IV as well as VI, XII, and XIV may be found in
the myxoid ECM (Table 2).
Other ECM molecules
Other structural molecules identified in the myxoid ECM
are fibronectin and tenascin C (Table 2). Fibronectin is a
fibril-forming glycoprotein existing in a dimeric or multi-
meric form. Each monomer contains several binding sites
for fibrin, heparin, DNA, and cells. Fibronectin molecules
consist of different repeats (types I, II, and III) and three
different sites that can be alternatively spliced (EDA, EDB,
and V). The dimeric, soluble form is produced by
hepatocytes and lacks the alternative EDA and EDB
variants. The multimeric form is extensively present in
granulation tissue, basement membrane, and on cell
surfaces and contains variable proportions of the EDA
and EDB domains [16]. Until now, fibronectin has only
been found in myxoid liposarcoma but might also be
present in the ECM of other myxoid lesions (Table 2).
Tenascin C is a highly conserved glycoprotein of the
ECM consisting of 300 kDa monomers, characteristically
assembled in 1,800 kDa hexamers [17, 18]. It consists of
several functionally independent domains of which the
number is dramatically increased by alternative splicing.
The N-terminal contains the cysteine-rich assembly do-
main, followed by EGF-like repeats, eight constant and up
to nine alternatively spliced fibronectin type III repeats and
a C-terminal fibrinogen-like globular domain [18]. Till
today, its presence has only been shown in myxoid areas of
epithelial but not (yet) in mesenchymal tumors (Table 2).
Functional role of the different constituents
in the myxoid extracellular matrix
Glycosaminoglycans
GAGs have both biophysical and biochemical functions
and play important roles in physiologic and neoplastic
processes (Table 3)[ 19]. Due to their high content of
sulfate and carboxyl groups, complex patterns of sulfation
and uronic acid epimerizations, GAG chains confer upon
PGs the diverse capacities to function as ideal physiological
barriers, reservoirs for signaling proteins, and binding
partners for structural macromolecules [13]. We have
Fig. 3 Myxoid ECM is a ubiquitously histological feature in
physiological and pathological conditions. Myxoid ECM is a
morphological feature in physiological and pathological conditions,
such as in myxedema due to increased production of HA. Myxoid
areas/changes are also commonly present in tumors (both of epithelial
and mesenchymal origin). In epithelial tumors, myxoid changes are
often a secondary phenomenon, whereas in mesenchymal tumors, they
are more frequently an intrinsic part of the tumor entity. This group of
so-called myxoid tumors of soft tissues contains an increasing number
of entities (e.g., myxofibrosarcoma, formerly called myxoid variant of
malignant fibrous histiocytoma), sometimes sustained by specific
distinct molecular/cytogenetic aberrations (e.g., myxoid liposarcoma)
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heterogeneous in composition and that the relative amount
of each GAG is tumor-type- and tumor-grade-dependent
[20]. Because of their negative charge, all GAGs, especially
HA, are able to trap water molecules. Interestingly, HA is
the common denominator in the myxoid ECM (Table 2).
This suggests that HA is the major contributor to the
edematous appearance of the myxoid ECM. As a result of
the biophysical properties of GAGs (their high viscosity
and low compressibility), they are ideal for tissue lubrica-
tion. On the other hand, their rigidity is responsible for the
structural integrity of tissues facilitating diffusion of
metabolites and cell migration [21]. The biochemical
properties of GAGs are mediated by specific binding to
other macromolecules. GAGs can bind to secreted pro-
teases and antiproteases, growth factors, structural ECM
proteins, and proteins expressed on (tumor) cells [22].
Chondroitin sulfate modulates cell fate as it appears to
prevent apoptosis and is involved in cell proliferation. Since
chondroitin sulfate is much more abundant in the ECM of
extraskeletal myxoid chondrosarcoma compared to intra-
muscular myxoma and myxofibrosarcoma, it might, there-
fore, play a role in the more malignant behavior of this
tumor [20]. Large multidomain ECM molecules such as
collagen types I, III, V, and XIV and fibronectin contain at
least one GAG binding site. This allows them to bind to
heparan and chondroitin sulfates on cells or in the ECM,
contributing to proper ECM formation.
Table 1 Myxoid tumors of soft tissue: overview of clinicopathological and genetic features
Myxoid tumors of soft tissue Age Sex Predilection site Molecular/cytogenetic aberrations References
Benign
Intramuscular myxoma (including
its cellular variant)
Adults F>M Thigh, shoulder, buttocks,
and rarely upper arm
GNAS1 mutations [34]
Myxoid neurothekeoma Young
adults
F>M Head, neck, and shoulders Loss of 22q [8]
Myxoid lipoma (myxolipoma) Any age F=M Head and neck Rearrangement of 13q and/or 16q [8]
Myxoid chondroma Adults M>F Hands and feet Extra copies of chromosome 5 or
12q13–15 rearrangement
[8]
Myxoid neurofibroma Any age M=F All over the body NF1 mutations [8]
Myxoid dermatofibroma Young
adults
F>M Lower extremities Unknown [42]
Cardiac myxoma Adults F>M Atria (predominantly left) PRKAR1α mutations in Carney
complex
[43]
Ossifying fibromyxoid tumor Elderly M>F Extremities and trunk Nonspecific cytogenetic aberrations [8]
Cutaneous myxoid cyst Any age F>M Distal and dorsal portions
of fingers (and toes)
Unknown [8]
Cutaneous myxoma (superficial
angiomyxoma)
Adults M>F Trunk, lower extremities,
head, and neck
PRKAR1α mutations in Carney
complex
[43]
Myxoid nodular fasciitis Young
adults
M=F Head, neck, and
extremities
Nonspecific cytogenetic aberrations [8, 44]
Locally aggressive
Odontogenic myxoma Young
adults
F>M Mandible and maxilla PRKAR1α mutations in rare cases
(not Carney complex)
[45]
Myxoinflammatory fibroblastic
sarcoma
Adults M=F Feet, lower leg t(1;10)(p22;q24) and amplification of
chromosome 3
[46]
Aggressive angiomyxoma Adults F>>M Inguinal region Rearrangement of 12q13-15 [8]
Malignant
Myxofibrosarcoma Elderly M=F Extremities, thigh Nonspecific cytogenetic aberrations [47, 48]
Extraskeletal myxoid
chondrosarcoma
Adults M>F Extremities and limb t(9;22)(q22;q12), t(9;17)(q22;q11) or t
(9;15)(q22;q21)
[49]
Low-grade fibromyxoid sarcoma Young
adults
M>F Proximal extremities
and trunk
t(7,16) (q33;p11) [50]
Myxoid liposarcoma Elderly M>F Lower extremities and
thigh
t(12;16)(q13;p11) or t(12;22)(q13;q12) [51]
Myxoid leiomyosarcoma of soft
tissue
Adults F>>M Limbs, female genitalia,
head, and neck
Nonspecific cytogenetic aberrations [52]
Myxoid malignant peripheral
nerve sheath tumor
Adults F=M Extremities, trunk NF1 and TP53 mutations, P16
deletions
[8, 53]
Myxoid dermatofibrosarcoma Adults M=F Trunk, groin, and
extremities
t(17;22)(q22;q13) [54]
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PGs exhibit a wide variety of functions due to their
structural diversity (Table 3). As PGs avidly bind proteins,
they are involved in all cellular processes concerning cell–
matrix, cell–cell, and ligand–receptor interactions. PGs are
known to have affinity for a variety of ligands, including
growth factors, cell adhesion molecules, ECM components,
Table 2 The composition of the myxoid ECM is heterogeneous but not lesion-specific
Proteoglycans Collagens
(types)
Other ECM components References
Non-neoplastic myxoid lesions
Follicular mucinosis HA [55]
Myxedema HA I (III) [56, 57]
Stenotic arteries Versican, biglycan, perlecan,
HA
I TBFbeta1 [58, 59]
Pseudoaneurysm Versican [60]
Endocardiosis HA [61]
Valvular degeneration of the heart I, III [62]
Myxoid tumors of soft tissue
Intramuscular myxoma KS, HA, C4S, C6S I, VI Albumin, IgGs [20, 34]
Myxofibrosarcoma KS, HA, C4S, C6S I, VI, XII,
XIV
Thrombospondin
Albumin, IgGs
[8, 20, 34]
Extraskeletal myxoid
chondrosarcoma
C4S, C6S, HA (aggrecan) I, III, VI (II,
IV)
Albumin, IgGs [20, 63]
Odontogenic myxoma C4S, C6S, DS, KS, HS, aggrecan, versican,
biglycan, decorin
[64]
Low-grade fibromyxoid sarcoma HA [65]
Myxoid neurothekeoma HA [66]
Myxoid lipoma (myxolipoma) HA [67]
Myxoid liposarcoma HA FN [68]
Myxoid chondroma HA, KS [69]
Myxoid neurofibroma HA, C4S, C6S [69]
Chondromyxoid fibroma Aggrecan I, III, VI [70]
Myxoid dermatofibroma HA [71]
Myxoid leiomyosarcoma HA [72]
Cardiac myxoma C4S, C6S, (HA) [73]
Ossifying fibromyxoid tumor IV (II) [74, 75]
Myxoinflammatory fibroblastic
sarcoma
A1AT, A1ACT [76]
Cutaneous myxoid cyst HA [77]
Aggressive angiomyxoma HA [78]
Cutaneous myxoma (superficial
angiomyxoma)
HA [79]
Myxoid areas in epithelial tumors
Breast carcinoma Aggrecan, versican, HA I, II, IV [80]
Pleiomorphic adenoma Lumican, perlecan, aggrecan,
C4S, C6S, DS, KS, HA
I, III, IV FGF2, Tenascin, FN,
ChM-I
[81–83]
Vulvar squamous cell carcinoma CD44, TGF-beta3 [84]
Mixed tumor of skin IV Tenascin, FN [85]
Cholangiocarcinoma Perlecan [86]
Miscellaneous tumors (nonsoft tissue, nonepithelial)
Myxopapillary ependymoma HA, CS, HS [87]
Myxoid mesothelioma HA [88]
Myxoid meningioma HA, CS [89]
KS keratin sulfate, HA hyaluronic acid, C4S chondroitin sulfate, C6S chondroitin 6 sulfate, DS dermatan sulfate, HS heparan sulfate
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Type and presence Physiology Pathology
C4S(CS-A) Sulfated galactosaminoglycan;
cartilage, skin and tendon
Binds Ca
2+,C u
2+ and Fe
2+ ions;
antioxidant (better then C6S and HA)
Decreased in OA, mediate adherence of
plasmodium infected red blood cells
C6S (CS-C) Sulfated galactosaminoglycan;
cartilage, brain secretory granules
Reduces proinflammatory cytokines,
MMPs, NO, and apoptosis
Laryngeal cancer, decreased in OA,
increased in early atherosclerotic lesions
DS (CS-B) Sulfated galactosaminoglycan; skin,
blood vessels, heart, tendons,
lungs
Regulation ECM integrity and cellular
signaling; DS selectively activates
heparin cofactor II that inactivates
thrombin; carcinogenesis, wound repair,
and fibrosis; DS binds water, coagulation
Dermatan sulfate accumulates abnormally
in several of the mucopolysaccharidosis
disorders and in myxomatous
degeneration. Involved in cardiovascular
disease, infection, fibrosis
HA Lack sulfation and epimerization
of glucuronic acid moiety to uronic
acid, the only GAG synthesized in
the cytoplasm at the plasma
membrane and also the only GAG
that is synthesized without core
protein. Connective, epithelial and
neural tissue. abundant in cartilage
and bone
Early development, tissue organization,
cell proliferation, facilitate migration and
condensation of mesenchymal cells,
participates in joint cavity formation,
binds and immobilizes aggrecan,
regulates osteoblast and osteoclast
function. HA works as a scaffold for
building PGs, suppresses cartilage
degeneration and reduce pain perception,
associated with cell adhesion and
motility, suppresses prostaglandin E2 and
IL-1 production, activates SRC, FAK,
ERK and PKC whereas interaction with
CD44 also regulates ERBB, PI3K, regu
lates phosphorylation of BAD and hence
promotes cell survival, contributes to cell
proliferation and migration, bone turn
over, involved in tissue repair in skin,
binds to receptor CD44
Used for treatment of osteoarthritis
HS Sulfated glucosaminoglycan; all
types of cells, highly abundant in
ECM of the skeleton
Coreceptors for morphogens, sequester
growth factors and cytokines to regulate
cell differentiation and growth, compose
ECM scaffolds that make physical
separation of the niche from cellular and
signaling influence of surrounding
environment, involved in skeletal
patterning, differentiation, growth and
homeostasis, critical for hematopoietic
stem cell inch, Ndst1 mutation causes
brain/skull defects and lung surfactant
problems resulting in perinatal lethality,
Ndst2 mutant have defective granule
formation in mast cells, stimulates
angiogenesis, osteocastogenesis, skeletal
patterning, differentiation and
homeostasis, coreceptor for morphogens,
sequester growth factors and cytokines to
regulate cell differentiation and growth,
FGF-binding, binds fibronectin
Sequesters chemokines or FGF towards
migrating tumor cells, promotes
metastasis, multiple osteochondromas
(MO)—benign bone cartilaginous tumor
caused by mutant in EXT1 or EXT2,
accumulated in mucopolysaccharidoses
KS Sulfated glucosaminoglycan;
N-glycan KSI or O-glycan KSII.
Highly abundant in cornea and
cartilage. Also found in epithelial
tissue, central nervous system
Maintains proper special organization of
the type I collagen fibrils and promotes
transparency of cornea, cellular
recognition of protein ligands, cell
motility
Corneal opacity and corneal dystrophy
(KS lacks GlcNAc sulfation), epithelial-
derived carcinoma cells, alerted sulfation
levels of KS was found in brain of
Alzheimer patients
Aggrecan O- and N-linked KSII, CS, DS,
KS (HS absent), cartilage
Maintains tissue hydration, contributes to
the mechanical properties of tissue,
inhibits migration of neural crest cells,
null mice show cartilage defects and
delay in bone development
Chondrodystrophy, nanomelia, cartilage
matrix deficiency (CMD), murine
brachymorphism (bm),
spondyloepimetaphyseal dysplasia
enhanced expression in chondroblastoma,
chondroma, chondrosarcoma,
osteosarcoma, decreased in squamous cell
carcinoma chondrodystrophy, nanomelia,
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ECM proteins with its C-type lectin motif, facilitating the
formation of networks permissive for cell growth [23]. For
example, aggrecan and versican associate tightly with both
HA, thereby maintaining tissue hydration. Due to the EGF-
like repeats, lecticans are directly involved in growth
control. Versican stimulates the proliferation of fibroblasts
and is highly expressed by fast-growing cells and present in
myxoid areas of both reactive and neoplastic (mesenchymal
and epithelial) lesions (Table 2)[ 24].
Small leucine-rich proteoglycans
SLRPs are structurally and functionally related ECM mole-
culesandabundantlyexpressedinconnectivetissues.Decorin
and biglycan bind to collagen and influence collagen fibrillo-
Table 3 (continued)
Type and presence Physiology Pathology
cartilage matrix deficiency,
spondyloepimataphyseal dysplasia
Biglycan CS, DS (HS absent), bone,
cartilage, skin, connective
tissue
Activates cell division, organization
of collage fibers, increased in vascular
injury, upregulates p27 and downregulates
cyclin A and proliferating cell nuclear
antigen, maintaining proper number of
mature osteoblasts and survival of bone
marrow stromal cells, organization of
collagen fibers, regulator of cell cycle,
binds TGF-beta
Overexpressed in pancreatic cancer
and hyperplasic thymus osteoporosis
Decorin CS, DS (HS absent),
connective tissue, cornea
Inhibits collagen fiber formation by
interaction with col I, col II, and col
VI, inhibits cell division, adhesion,
increased in vascular injury, downregulates
Erbb2 and MAP kinases, upregulates p21
CDK inhibitor leading to inhibition of cell
proliferation and specific induction of
apoptosis in transformed cells. maintaining
proper number of mature osteoblasts and
maintaining survival of bone marrow
stromal cells, bind nonfibril collagens
XII and XIV, regulates cell proliferation,
binds TGF-beta, mediates EGF signaling
by binding to EGFR
Antiproliferative properties in tumor
growth, overexpressed in colorectal
carcinoma, colon adenocarcinoma,
melanoma, osteosarcoma, basal cell
carcinoma,
inhibits migration of MG-63 osteosarcoma
cells, reduced decorin levels were found
in lung adenocarcinoma, squamous
carcinoma, breast carcinoma, hepatocellular
carcinoma and ovarian tumors, may
regulate tumor angiogenesis, overexpression
is often associated with shift from DS to
CS, osteoporosis
Lumican KS, cornea Upregulates p27 and downregulates
cyclin A and proliferating cell nuclear
antigen, regulates collagen fibril
organization and circumferential growth,
corneal transparency, and epithelial cell
migration and tissue repair
Upregulated in pancreatic, colorectal
and breast cancers, stroma of salivary
pleiotropic adenoma, reduced expression
is correlated with progression of breast
carcinoma
Perlecan HS, CS, cartilage, limb bud
mesenchyme, articular
cartilage, bone marrow stroma,
all basal membranes,
vasculature
Growth factor signaling, collagen
fibrillogenesis, structural stability,
vasculogenesis, endorepellin,
antiangiogenic factor, chondrocyte
proliferation and differentiation,
collagen I and II fibrillogenesis,
vasculogenesis, mediator of Shh
signaling, Wnt signaling, TGF-beta
signaling in the skeleton, regulates
FGF2 signaling
Schwartz–Jampel syndrome, dyssegmental
dysplasia Silverman–Handmaker
type (DDSH), perlecan-null
embryo chondroplasia,
prostate tumor metastasis
Versican C6S>C4S>DS (HS, KS absent),
connective tissue, aorta, brain;
fibroblasts. important for vascular
biology
Lipid retention, modification and
accumulation, hydration of ECM,
cell proliferation, migration, embryo
development, binds HA, CD44, and
chemokines
Promotes tumor growth and spread, expressed
in the stroma of nearly all human cancers
(prostate, breast, lung, ovarian cancers
and odontogenic tumors, melanoma, brain
tumors, pharyngeal squamous cell
carcinoma, keratinocyte tumors,
atherosclerosis)
188 Virchows Arch (2010) 456:181–192genesis and ECM assembly in various ways: (a) due to its
curvedshape,decorinisabletobindtocollagentypesI,II,VI,
and XIV linking them together and to fibronectin [25], (b) by
decorating collagen fibers, decorin protects them from
degradation by collagenases [25, 26], and (c) by its attached
GAG chain, decorin is capable of modulating the activity of
TGF-beta, which plays a central role in fibrogenesis [13, 25,
27]. Biglycan- and decorin-deficient mice show irregular and
defective collagen fibrils, fragile skin, and a phenotype that
closely resembles that of patients with Ehlers–Danlos
syndrome [28]. In wound healing, there is a spatial temporal
regulation of the expression of the different SLRPs (decorin,
lumican, fibromodulin, and biglycan) tightly controlling the
transformation of the myxoid ECM of granulation tissue
towards fibrotic scar formation [29]. Myxoid areas in
pleomorphic adenoma of the salivary gland and odontogenic
myxoma lack expression of biglycan, lumican, and decorin,
whereas these SLRPs are diffusely present in the fibrotic
parts of the ECM of these tumors (Table 2). This suggests
that the absence of SLRPs might contribute to impaired
ECM formation resulting in a mere myxoid morphology.
Collagens
As form follows function [30], different collagens have
different properties. In the initial phase of wound healing,
collagen type I is quickly produced by fibroblasts and
replaced by collagen type III in the later stage of scar
formation [29]. The FACIT collagen types XII and XIV do
not form collagen fibrils themselves but associate with
fibrillary collagens, such as collagen type I, decorin, and
GAGs, linking them together [31–33]. Collagen type XIV
interacts with dermatan sulfate sequences on the single
chondroitin sulfate/dermatan sulfate chain attached to
decorin, thereby providing a link between the fibril-forming
and the fibril-associated collagens [32]. Collagen type XIV is
expressed significantly higher in grade I myxofibrosarcoma
than in intramuscular myxoma (including its cellular variant)
[34]. On one hand, this might have implications for ECM
assembly and tumor development, thereby playing a poten-
tial role in the different biology and clinical behavior of these
different entities; on the other hand, the effect of cell–ECM
interaction in these tumors might work the other way around,
as collagen XIV induces differentiation of fibroblastic cells
[35]. Higher expression of collagen XIV in myxofibrosar-
coma is associated with a more mature morphology of the
tumor cells compared to intramuscular myxoma [5].
Other ECM molecules
Fibronectin plays a role in various biological processes,
such as wound healing, host defense, regulation of ECM
assembly, adhesion, and proliferation [36]. It is also a key
molecule in cell–ECM signaling, and aberrant activation of
fibronectin–ECM signaling has been described in many
tumors [37]. Likewise, tenascin C is an ECM glycoprotein
of which the spatial and temporal expression is tightly
regulated during fetal development [38]. It has been shown
that the tenascin C-encoding gene is upregulated in several
pathologic conditions, such as wound healing, inflamma-
tion, and malignancies [38]. Elevated tenascin C expression
has been found in epithelial and mesenchymal tumors, both
in tumor and stromal cells, and is associated with
unfavorable disease outcome (Table 2)[ 18]. Tenascin C
attaches to cells via integrins, though the effect of this
interaction on cellular signaling and tumor development is
largely unknown [39].
Putative relevance for routine pathology practice
In routine general practice, one encounters a group of
tumors, mesenchymal as well as epithelial, which may
show variable degrees of myxoid appearance of their ECM.
Myxoid tumors of soft tissue, the focus of this paper,
encompass a heterogeneous group of lesions characterized
by a marked abundance of extracellular mucoid/myxoid
matrix (Table 1). This group of tumors exhibits a broad
range of biological behavior varying from those which are
entirely benign via locally aggressive (but nonmetastasiz-
ing) behavior to those which are frankly malignant; hence,
accurate histopathological diagnosis is essential for appro-
priate clinical management. Till today, there have been no
convincing data which demonstrate that the composition of
the myxoid matrix significantly differ between tumors (both
of mesenchymal and/or epithelial origin) and reactive
lesions. From a biochemical point of view, the term
“myxoid” is best considered a wastebasket of many
different proteins and other (macro)molecules which might
all have a different function (Tables 2 and 3). While
determination of the different GAGs in myxoid tumors is
interesting from a research point of view, Scott’s critical
electrolyte concentration (CEC) method is no longer a
routinely used technique by pathologists. Most myxoid
tumors of soft tissue tumors contain HA (Table 2), and
consequently, its detection is no longer regarded as
discriminatory in differential diagnoses. Outside the aca-
demic setting (where recourse to sophisticated biochemical
and molecular genetics techniques is generally not possi-
ble), when confronted with challenging myxoid lesions, the
diagnostic process relies primarily on careful and discrim-
inatory histopathological evaluation in order to reach a
correct diagnosis. Routine histological criteria (e.g., tumor
demarcation, growth and vascular pattern, and nuclear
atypia) remain the hallmarks of diagnosis. (Immuno-)
histochemistry may be useful as a adjunct in the setting of
Virchows Arch (2010) 456:181–192 189certain differential diagnostic considerations, but is often
not discriminatory and, therefore, not diagnostically useful
[8]. Molecular cytogenetics is of increasing importance for
diagnosis in difficult cases, as the genetic makeup of an
increasing number of myxoid tumors of soft tissue is being
elucidated (Table 1). Next to genetic causes (such as driver
mutations, translocations, or gene amplifications), environ-
mental factors have been shown to play an important role in
tumorigenesis of both epithelial and mesenchymal tumors
[40]. Virchow already mentioned the possible relationship
between the histological appearance of the myxoid ECM of
tumors and their differences in biological behavior [1]. It is
very tempting to believe that GAGs and PGs play an
important role in the biology of myxoid lesions rather than
just being a byproduct of (myo)fibroblastic differentiation.
Intramuscular myxoma expresses significantly less decorin
and collagen VI and XIV (both protein and mRNA level)
than grade I myxofibrosarcoma [34]. Next to decorin, liquid
chromatography–mass spectrometry revealed other SLRPs
(i.e., lumican, prolargin 4, biglycan) present in tumor
lysates of grade I myxofibrosarcoma but not of intramus-
cular myxoma [34]. This suggest that ECM formation in
intramuscular myxoma is impaired compared to grade I
myxofibrosarcoma. Increased ECM rigidity activates integ-
rins and subsequently leads to stimulation of the rho/Rock
pathway and cell migration and invasion [41]. In this
respect, the morphological similarity between the process of
wound healing and myxoid changes/areas in (non)neoplas-
tic lesions is rather striking. In the early phase, granulation
tissue shows a loose, edematous/myxoid ECM rich in
GAGs. In the subsequent phase, there is structural
organization of the ECM with deposition of collagens
produced by myofibroblasts which locally (de)differentiate
from fibroblast/smooth muscle cells or are derived from the
bone marrow. The term “myxoid” might not only be
synonymous with (aberrant turnover and) the presence of
GAGs, but also reflects the absence of proper ECM
assembly or incomplete ECM formation. This might well
explain that a myxoid morphology of the ECM is not
specific at all and can be seen in reactive/non-neoplastic
processes as well as in benign and malignant tumors
(Fig. 3). As already extensively discussed in this paper,
the ECM is dependent on the interplay of various macro-
molecules (polysaccharides and proteins) which determine
its texture and consistency. It is becoming increasingly clear
that, within this group of lesions, various tumor types may
show differences in the biological composition of their
myxoid matrix, as determined by differences in the relative
proportions of the constituent macromolecules and the
presence or absence of specific stromal constituents.
Clearly, this is an important and highly relevant area for
further research in order to identify tumor-specific markers
and to consequently develop economically viable and user-
friendly detection methods to facilitate the diagnostic
process and ensure increasingly accurate histopathologic
diagnosis.
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